In our latest Pharma15 Live! COVID-19 special report, BBK's President Matt Kibby introduces a new framework for helping clinical trial sponsors maintain study momentum during COVID-19 and beyond.
The framework features strategies for minimizing disruption during four key stages of the study lifecycle.